349 related articles for article (PubMed ID: 22205715)
1. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
[TBL] [Abstract][Full Text] [Related]
2. Increased Expression of Multiple Co-Inhibitory Molecules on Malaria-Induced CD8
Brandi J; Riehn M; Hadjilaou A; Jacobs T
Front Immunol; 2022; 13():878320. PubMed ID: 35874786
[TBL] [Abstract][Full Text] [Related]
3. PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish.
Hu CB; Huang C; Wang J; Hong Y; Fan DD; Chen Y; Lin AF; Xiang LX; Shao JZ
J Immunol; 2023 Sep; 211(5):816-835. PubMed ID: 37486225
[TBL] [Abstract][Full Text] [Related]
4. THEMIS promotes T cell development and maintenance by rising the signaling threshold of the inhibitory receptor BTLA.
Mélique S; Vadel A; Rouquié N; Yang C; Bories C; Cotineau C; Saoudi A; Fazilleau N; Lesourne R
Proc Natl Acad Sci U S A; 2024 May; 121(20):e2318773121. PubMed ID: 38713628
[TBL] [Abstract][Full Text] [Related]
5. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
6. Blockade of BTLA alone or in combination with PD-1 restores the activation and proliferation of CD8
Liu Y; Zhao Z; Su S; Li Y; Chen N; He L; Dong M; Xu B; Zhang Z; Zhou Y; Zhu Z
Vet Microbiol; 2024 Mar; 290():110004. PubMed ID: 38281324
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.
Stühler V; Alemi B; Rausch S; Stenzl A; Schwab M; Schaeffeler E; Bedke J
World J Urol; 2024 Jan; 42(1):53. PubMed ID: 38244072
[TBL] [Abstract][Full Text] [Related]
8. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme.
Goods BA; Hernandez AL; Lowther DE; Lucca LE; Lerner BA; Gunel M; Raddassi K; Coric V; Hafler DA; Love JC
PLoS One; 2017; 12(9):e0181538. PubMed ID: 28880903
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer.
Li X; Wang R; Fan P; Yao X; Qin L; Peng Y; Ma M; Asley N; Chang X; Feng Y; Hu Y; Zhang Y; Li C; Fanning G; Jones S; Verrill C; Maldonado-Perez D; Sopp P; Waugh C; Taylor S; Mcgowan S; Cerundolo V; Conlon C; McMichael A; Lu S; Wang X; Li N; Dong T
Front Oncol; 2019; 9():1066. PubMed ID: 31709176
[No Abstract] [Full Text] [Related]
10. Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
Pagliano O; Morrison RM; Chauvin JM; Banerjee H; Davar D; Ding Q; Tanegashima T; Gao W; Chakka SR; DeBlasio R; Lowin A; Kara K; Ka M; Zidi B; Amin R; Raphael I; Zhang S; Watkins SC; Sander C; Kirkwood JM; Bosenberg M; Anderson AC; Kuchroo VK; Kane LP; Korman AJ; Rajpal A; West SM; Han M; Bee C; Deng X; Schebye XM; Strop P; Zarour HM
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35316223
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.
Teagle AR; Castro-Sanchez P; Brownlie RJ; Logan N; Kapoor SS; Wright D; Salmond RJ; Zamoyska R
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056892
[TBL] [Abstract][Full Text] [Related]
12. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.
Cianciotti BC; Magnani ZI; Ugolini A; Camisa B; Merelli I; Vavassori V; Potenza A; Imparato A; Manfredi F; Abbati D; Perani L; Spinelli A; Shifrut E; Ciceri F; Vago L; Di Micco R; Naldini L; Genovese P; Ruggiero E; Bonini C
Front Immunol; 2024; 15():1315283. PubMed ID: 38510235
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
Faria C; Gava F; Gravelle P; Valero JG; Dobaño-López C; Van Acker N; Quelen C; Jalowicki G; Morin R; Rossi C; Lagarde JM; Fournié JJ; Ysebaert L; Laurent C; Pérez-Galán P; Bezombes C
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899130
[TBL] [Abstract][Full Text] [Related]
14. Peptides targeting the BTLA-HVEM complex can modulate T cell immune response.
Wojciechowicz K; Kuncewicz K; Lisowska KA; Wardowska A; Spodzieja M
Eur J Pharm Sci; 2024 Feb; 193():106677. PubMed ID: 38128840
[TBL] [Abstract][Full Text] [Related]
15. TIM-3
Minnie SA; Waltner OG; Zhang P; Takahashi S; Nemychenkov NS; Ensbey KS; Schmidt CR; Legg SRW; Comstock M; Boiko JR; Nelson E; Bhise SS; Wilkens AB; Koyama M; Dhodapkar MV; Chesi M; Riddell SR; Green DJ; Spencer A; Furlan SN; Hill GR
Sci Immunol; 2024 Apr; 9(94):eadg1094. PubMed ID: 38640253
[TBL] [Abstract][Full Text] [Related]
16. A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells.
Cameron CM; Richardson B; Golden JB; Phoon YP; Tamilselvan B; Pfannenstiel L; Thapaliya S; Roversi G; Gao XH; Zagore LL; Cameron MJ; Gastman BR
Front Oncol; 2023; 13():1200387. PubMed ID: 38023136
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients.
Al-Mterin MA; Alsalman A; Elkord E
Front Immunol; 2022; 13():870283. PubMed ID: 35432324
[TBL] [Abstract][Full Text] [Related]
18. CD8-targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T cell pool.
Kaptein P; Slingerland N; Metoikidou C; Prinz F; Brokamp S; Machuca-Ostos M; de Roo G; Schumacher TNM; Yeung YA; Moynihan KD; Djuretic IM; Thommen DS
Cancer Discov; 2024 Apr; ():. PubMed ID: 38563969
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma.
Hafler D; Lu B; Lucca L; Lewis W; Wang J; Nogeuira C; Heer S; Axisa PP; Buitrago-Pocasangre N; Pham G; Kojima M; Wei W; Aizenbud L; Bacchiocchi A; Zhang L; Walewski J; Chiang V; Olino K; Clune J; Halaban R; Kluger Y; Coyle A; Kisielow J; Obermair FJ; Kluger H
Res Sq; 2024 Feb; ():. PubMed ID: 38464315
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM
Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
